BFEC
ESPR

Benjamin F. Edwards & Company’s Esperion Therapeutics ESPR Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1K Hold
325
– – ﹤0.01% 2086
2024
Q1 		$1K Hold
325
– – ﹤0.01% 2073
2023
Q4 		$1K Hold
325
– – ﹤0.01% 2032
2023
Q3 		$0 Hold
325
– – ﹤0.01% 1760
2023
Q2 		$0 Hold
325
– – ﹤0.01% 1780
2023
Q1 		$1K Hold
325
– – ﹤0.01% 1720
2022
Q4 		$2K Hold
325
– – ﹤0.01% 1721
2022
Q3 		$2K Sell
325
-50
-13% -$343 ﹤0.01% 1704
2022
Q2 		$2K Hold
375
– – ﹤0.01% 1678
2022
Q1 		$2K Hold
375
– – ﹤0.01% 1650
2021
Q4 		$2K Hold
375
– – ﹤0.01% 1628
2021
Q3 		$5K Hold
375
– – ﹤0.01% 1518
2021
Q2 		$8K Hold
375
– – ﹤0.01% 1417
2021
Q1 		$11K Hold
375
– – ﹤0.01% 1326
2020
Q4 		$10K Buy
+375
New +$11.2K ﹤0.01% 1274
2018
Q1 		– Sell
-152
Closed -$10K – 1622
2017
Q4 		$10K Hold
152
– – ﹤0.01% 1196
2017
Q3 		$8K Buy
+152
New +$7.33K ﹤0.01% 1221

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Benjamin F. Edwards & Company's ESPR Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Esperion Therapeutics (ESPR) position steady in Q2 2024 at 325 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Benjamin F. Edwards & Company first reported a position in ESPR in Q3 2017 and has held it in 17 quarters since. The position peaked at $11K in Q1 2021. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Benjamin F. Edwards & Company held 325 shares of Esperion Therapeutics worth $1K as of Q2 2024.
  • Benjamin F. Edwards & Company left its Esperion Therapeutics share count unchanged in Q2 2024.
  • Esperion Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2086 holding.
  • Benjamin F. Edwards & Company first reported a position in Esperion Therapeutics in Q3 2017 and has held it in 17 quarters since.
  • Benjamin F. Edwards & Company's Esperion Therapeutics position peaked at $11K in Q1 2021.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.